News / Taiwan / cnyes
Tensei Cleared for OTC Listing as AI-Driven Strategy Boosts Revenue
Consumer Non-Durables · Household/Personal Care · cnyes · 2026-09-10
7889
Health supplement firm Tensei has received OTC approval for its listing, reporting a 10.61% YoY revenue increase for the first eight months of 2026.
What Happened
Listing Progress: Tensei, a developer of human and pet health supplements, has officially received approval from the OTC for its upcoming listing. The company continues to scale its operations, demonstrating a healthy and sustainable growth trajectory.
Financial Performance: Tensei reported August 2026 revenue of NT$69.67 million, bringing its cumulative revenue for the first eight months of the year to NT$602 million, a 10.61% increase year-over-year. The company also posted a solid EPS of NT$2.24 for the first half of 2026.
Growth Strategy: The company employs a multi-brand strategy, with core brands like 'Damo' and 'Pet Era' maintaining steady growth, while new brands like 'Oshima' and 'Aopei' show triple-digit growth. Digital e-commerce channels have been a key driver, with revenue from these platforms rising nearly 20%.
AI Integration: By leveraging CDP platforms and AI-driven marketing tools, Tensei has successfully optimized its advertising spend and improved customer loyalty. This digital transformation has allowed the company to maintain strong sales momentum despite the cooling of traditional e-commerce traffic.